Advertisement

Topics

Ocugen receives FDA Orphan designation for ocular graft versus host disease

15:25 EDT 10 Aug 2017 | CentreWatch

Ocugen, a clinical stage biopharmaceutical company developing novel treatments for sight-threatening diseases, announced the FDA has granted orphan drug designation (ODD) for OCU300 (brimonidine tartrate) for the treatment of ocular graft versus host disease (oGVHD). Ocular GVHD is a common complication that occurs in 40-60% of patients who have undergone allergenic hematological stem cell transplantation […]

The post Ocugen receives FDA Orphan designation for ocular graft versus host disease appeared first on CenterWatch News Online.

Original Article: Ocugen receives FDA Orphan designation for ocular graft versus host disease

NEXT ARTICLE

More From BioPortfolio on "Ocugen receives FDA Orphan designation for ocular graft versus host disease"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...